CSIMarket
 



Prevail Therapeutics Inc   (PRVL)
Other Ticker:  
 
 



 

What are Prevail Therapeutics Inc's Business Segments?



Prevail Therapeutics Inc is a biotechnology company specializing in developing gene therapies for patients with neurodegenerative diseases. The company focuses on creating innovative treatments that target specific genetic mutations associated with these diseases.

Segments:
Prevail Therapeutics operates in the biotechnology and pharmaceutical industry, specifically in the field of gene therapy. The company's main segment is the development and commercialization of gene therapies for neurodegenerative disorders.

Products:
Prevail Therapeutics is primarily focused on developing gene therapies to treat neurodegenerative diseases caused by specific genetic mutations. Some of their key products include:

1. PR001: This is a gene therapy product being developed for the treatment of Parkinson's disease with a genetic GBA1 mutation. It aims to restore the function of the beta-glucocerebrosidase enzyme, which is deficient in individuals with this mutation.

2. PR006: This product is being developed for the treatment of frontotemporal dementia with a GRN mutation. It aims to increase the production of progranulin, a protein that is reduced in patients with this mutation.

Services:
In addition to the development of gene therapies, Prevail Therapeutics also offers various services related to their research and development efforts. These include:

1. Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of their gene therapy products. These trials involve collaborating with medical centers and recruiting eligible patients for participation.

2. Research Collaborations: Prevail Therapeutics actively engages in research collaborations with academic institutions, other biotechnology companies, and pharmaceutical partners. These collaborations involve sharing knowledge, resources, and expertise to advance the development of gene therapies for neurodegenerative diseases.

3. Patient Support and Advocacy: Prevail Therapeutics recognizes the importance of providing support to patients and their families. They engage with patient groups and advocate for improved access to therapies and better healthcare policies for individuals with neurodegenerative disorders.

Overall, Prevail Therapeutics Inc primarily focuses on developing gene therapies to address specific genetic mutations related to neurodegenerative diseases. Their products aim to provide innovative treatment options, while their services involve conducting clinical trials, engaging in research collaborations, and supporting patients and advocacy initiatives.
   

Prevail Therapeutics Inc Tax Rate Companies within the Biotechnology & Pharmaceuticals Industry



To get more information on Prevail Therapeutics Inc's segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com